Utilization of Oligonucleotides’ Half-Life to Optimize Dosing Regiment for Desirable Efficacy & Reduced CNS Toxicity
Time: 2:00 pm
day: Conference Day One
Details:
- Explore how chemical modifications and structural engineering can make oligos more resistant to nuclease degradation
- Understand the impact of half-life extension on dosing frequency, therapeutic window, and patient compliance
- Learn how conjugation to long-circulating carriers like antibodies can enhance PK/PD profiles and tissue retention
Speakers:
